Christina Giannakou
Overview
Explore the profile of Christina Giannakou including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
94
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Giannakou C, Park M, Bosselaers I, de Jong W, van der Laan J, Van Loveren H, et al.
Wiley Interdiscip Rev Nanomed Nanobiotechnol
. 2020 Apr;
12(5):e1633.
PMID: 32266791
Various nanomedicinal products (NMPs) have been reported to induce an adverse immune response, which may be related to their tendency to accumulate in or target cells of the immune system....
2.
Giannakou C, Aimonen K, van Bloois L, Catalan J, Geertsma R, Gremmer E, et al.
Nanomedicine (Lond)
. 2019 May;
14(10):1231-1246.
PMID: 31124759
Nanomaterials and nanomedicinal products tend to interfere with various commonly used assays, including regulatory required endotoxin detection methods for medicines. We developed a method to quantify endotoxin levels that is...
3.
Brand W, Noorlander C, Giannakou C, de Jong W, Kooi M, Park M, et al.
Int J Nanomedicine
. 2017 Sep;
12:6107-6129.
PMID: 28883724
Due to their specific properties and pharmacokinetics, nanomedicinal products (NMPs) may present different toxicity and side effects compared to non-nanoformulated, conventional medicines. To facilitate the safety assessment of NMPs, we...
4.
Kettler K, Giannakou C, de Jong W, Hendriks A, Krystek P
J Nanopart Res
. 2016 Oct;
18(9):286.
PMID: 27774037
Human health risks by silver nanoparticle (AgNP) exposure are likely to increase due to the increasing number of NP-containing products and demonstrated adverse effects in various cell lines. Unfortunately, results...
5.
Kettler K, Krystek P, Giannakou C, Hendriks A, de Jong W
J Nanopart Res
. 2016 Jul;
18:182.
PMID: 27433139
The increasing number of nanotechnology products on the market poses increasing human health risks by particle exposures. Adverse effects of silver nanoparticles (AgNPs) in various cell lines have been measured...
6.
Giannakou C, Park M, de Jong W, Van Loveren H, Vandebriel R, Geertsma R
Int J Nanomedicine
. 2016 Jul;
11:2935-52.
PMID: 27382281
Nanomaterials (NMs) are attractive for biomedical and pharmaceutical applications because of their unique physicochemical and biological properties. A major application area of NMs is drug delivery. Many nanomedicinal products (NMPs)...
7.
Braakhuis H, Giannakou C, Peijnenburg W, Vermeulen J, Van Loveren H, Park M
Nanotoxicology
. 2016 Jan;
10(6):770-9.
PMID: 26809698
To study the effects of nanomaterials after inhalation, a large number of in vitro lung models have been reported in literature. Although the in vitro models contribute to the reduction...